WINSTON-SALEM, N.C.--(BUSINESS WIRE)--Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics™, today announced the initiation of a Phase 2 exploratory study of TC-5214, a nicotinic channel blocker, as an augmentation therapy for resistant hypertension. TC-5214 is also being studied in an ongoing Phase 2b clinical trial as an augmentation therapy for major depressive disorder.
